<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04746495</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00170418</org_study_id>
    <secondary_id>1K23HL128909-01A1</secondary_id>
    <nct_id>NCT04746495</nct_id>
  </id_info>
  <brief_title>Effect of Eplerenone on Novel Biomarkers of Mineralocorticoid Receptor Activation (ENOVA)</brief_title>
  <acronym>ENOVA</acronym>
  <official_title>Effect of Eplerenone on Novel Biomarkers of Mineralocorticoid Receptor Activation (ENOVA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This blinded cross-over clinical trial will enroll participants with mild stage 1&#xD;
      hypertension to evaluate whether urinary extracellular transcript abundance predicts response&#xD;
      to an mineralocorticoid receptor (MR) antagonist, eplerenone.&#xD;
&#xD;
      Eligible participants will have a 2 week wash-in period followed by 4 weeks of treatment with&#xD;
      placebo or eplerenone. There will be a 2 week wash out period from study medications and then&#xD;
      participants will take the other drug (placebo or eplerenone) for 4 weeks. In addition,&#xD;
      participants will also provide urine and blood samples during the trial, have physical&#xD;
      assessments, and be monitored for safety.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Lab results will be reviewed by an un-blinded co-investigator.&#xD;
Dose adjustments will be done by an un-blinded co-investigator who is licensed to prescribe the study drug.&#xD;
The study blind will be broken on completion of the clinical study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) Cycle threshold (Ct) value of mineralocorticoid receptor-regulated gene messenger ribonucleic acid (mRNA)</measure>
    <time_frame>Week 6 (after first study treatment)</time_frame>
    <description>Cycle threshold of urinary mRNA biomarker following treatment with placebo and following treatment with eplerenone will be measured using RT-qPCR.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RT-qPCR Ct value of mineralocorticoid receptor-regulated gene mRNA</measure>
    <time_frame>Week 12 (after second study treatment)</time_frame>
    <description>Cycle threshold of urinary mRNA biomarker following treatment with placebo and following treatment with eplerenone will be measured using RT-qPCR.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be randomized to receive 4 weeks of placebo and then 4 weeks of Eplerenone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eplerenone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to receive 4 weeks of Eplerenone and then 4 weeks of Placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will go through a 2-week wash-in period. During the wash-in period, the participant will be asked not to take their usual antihypertensive medications for their mild hypertension. After the 2-week wash-in period, the participants will begin a 4-week treatment period and will take a placebo once a day for 4 weeks. After the 4 weeks, the participants will have a 2-week wash-out period where they will be off the study treatment. After the 2-week wash-out period, the participants will begin the Eplerenone treatment for another 4 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone 50mg</intervention_name>
    <description>Participants will go through a 2-week wash-in period. During the wash-in period, the participant will be asked not to take their usual antihypertensive medications for their mild hypertension. After the 2-week wash-in period, the participants will begin a 4-week treatment period of Eplerenone for 4 weeks. After the 4 weeks, the participants will have a 2-week wash-out period where they will be off the study treatment. After the 2-week wash-out period, the participants will then begin the Placebo treatment for another 4 weeks.</description>
    <arm_group_label>Eplerenone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  History of mild stage 1 systemic hypertension as defined by:&#xD;
&#xD;
               1. Systolic blood pressure (SBP) ≥ 140 millimeters of Mercury (mmHg) or diastolic&#xD;
                  blood pressure (DBP) ≥ 90 mmHg on 2 occasions and&#xD;
&#xD;
               2. Treatment with 1-2 antihypertensive medications (stable dose for 6 weeks)&#xD;
&#xD;
                  Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant, breastfeeding, or unwilling to practice birth control during participation&#xD;
             in the study.&#xD;
&#xD;
          -  Stage 2 hypertension (history of blood pressure ≥ 160/100 mmHg)&#xD;
&#xD;
          -  History of hypertensive urgency, hypertensive crisis, or hospitalizations for&#xD;
             hypertension&#xD;
&#xD;
          -  Current mineralocorticoid antagonist use&#xD;
&#xD;
          -  Type II Diabetes with microalbuminuria&#xD;
&#xD;
          -  Primary adrenal insufficiency&#xD;
&#xD;
          -  Current glucocorticoid use&#xD;
&#xD;
          -  Electrolyte abnormality on baseline laboratory assessment&#xD;
&#xD;
          -  Current potassium supplementation&#xD;
&#xD;
          -  Positive test for leukocyte esterase on urinalysis&#xD;
&#xD;
          -  Creatinine clearance &lt; 50 mL/min on baseline laboratory assessment&#xD;
&#xD;
          -  Hyperkalemia&#xD;
&#xD;
          -  Potassium-sparing diuretics (e.g., amiloride, spironolactone, or triamterene)&#xD;
&#xD;
          -  Serum potassium &gt;5.0 milliequivalents per liter (mEq/L) on baseline laboratory&#xD;
             assessment&#xD;
&#xD;
          -  Current use of strong CYP3A4 inhibitors (some include: ketoconazole, itraconazole,&#xD;
             nefazodone, troleandomycin, clarithromycin, ritonavir, and nelfinavir).&#xD;
&#xD;
          -  Serum creatinine &gt; 1.5 mg/dL in males on baseline laboratory assessment&#xD;
&#xD;
          -  Serum creatinine &gt; 1.3 mg/dL in females&#xD;
&#xD;
          -  Current beta blocker use&#xD;
&#xD;
          -  Any other condition thought by the Principal Investigator to place the participant at&#xD;
             increased risk of injury during the clinical trial or compromise the scientific&#xD;
             integrity of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J Brian Byrd, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christiana Hench</last_name>
    <phone>734-647-1119</phone>
    <email>cmhench@umich.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>J Brian Byrd, MD, MS</last_name>
    <phone>734-998-7991</phone>
    <email>jbbyrd@umich.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>J Brian Byrd, MD, MS</last_name>
      <phone>734-998-7991</phone>
      <email>jbbyrd@umich.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>February 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>J Brian Byrd, MD, MS</investigator_full_name>
    <investigator_title>Assistant Professor of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>mineralocorticoid</keyword>
  <keyword>mineralocorticoid receptor</keyword>
  <keyword>aldosterone</keyword>
  <keyword>eplerenone</keyword>
  <keyword>blood pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eplerenone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We will de-identify participant information and will share it with a trusted repository, such as National Institutes of Health (NIH) Figshare or The Inter-university Consortium for Political and Social Research (ICPSR).&#xD;
We will de-identify and share data obtained from analyzing urinary mRNA biomarkers and measuring the systolic and diastolic blood pressure following consumption of a high-sodium and low-sodium diet. Additionally, specific lab values that support the validity and quality of the study treatment will be shared in a trusted repository.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>De-identified data will be deposited into a repository within 1 year of the conclusion of the study.</ipd_time_frame>
    <ipd_access_criteria>No additional access restrictions will be placed on the de-identified data, beyond those required by the repository to access or download the data.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

